Here at METUPUK, we know drug access is a big issue for all metastatic breast cancer patients. There have been huge leaps and bounds made in terms of research, knowledge
How much is a year of life worth? Madeleine Meynell
How much is a year of life worth? Everyone’s life has a price on it but, for most healthy people, this is not something that occupies their waking thoughts. A
My cost of living crisis – Helen Crawford
I was just 39 years old, a mother of three young girls, facing a life expectancy of two to three years post-secondary breast cancer diagnosis. My chance to see my
Tassia Haines
We are heartbroken to share the news that Tassia Haines has died. A member of METUPUK and our Executive Lead for Wales, Tass had been a significant campaigner for MBC
Asha Umrawsingh
METUPUK are saddened by the news that one of our members and friend Asha Umrawsingh has died. Asha’s diagnosis and access to treatment was a roller coaster of how strict
METUPUK at the UK Interdisciplinary Breast Cancer Symposium
METUPUK (Metastatic Exchange To Unleash Power) attended the 2024 United Kingdom’s Interdisciplinary Breast Cancer Symposium in Birmingham, hosted by Breast Cancer Now and supported by numerous partners. It was a
PARP inhibitor Talazoparib recommended by NICE for the treatment of hereditary BRCA mutated metastatic breast cancer
METUPUK are delighted by the National Institute of Clinical Excellence (NICE) decision to recommend Talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with germline